Glenmark Pharmaceuticals Limited has informed the Exchange about Completion of transfer of Company's Consumer Care business
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glenmark Pharmaceuticals has completed the transfer of its Consumer Care business to Glenmark Consumer Care Limited, which is a wholly owned subsidiary of the company. This follows earlier intimations dated August 14, 2025 and September 15, 2025 regarding the proposed transfer. The move appears to be an internal restructuring to house the consumer care operations in a dedicated subsidiary entity. No financial details, deal value, or valuation figures were disclosed in this filing.
Since the Consumer Care business has been moved to a wholly owned subsidiary, the overall consolidated financials of Glenmark Pharmaceuticals remain unchanged. Shareholders should not expect any change in ownership or economic interest, though the restructuring may enable sharper focus on the core pharma business and the consumer care segment separately.